Welcome to our dedicated page for PARK HA BIOLOGICAL TECHNOLOGY SEC filings (Ticker: BYAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Park Ha Biological Technology Co., Ltd.'s SEC filings document the regulatory record of a Cayman Islands foreign private issuer with operating subsidiaries that sell Park Ha skincare and cosmetic products in China. Current reports on Form 6-K cover Nasdaq listing compliance, board changes, shareholder voting matters and amendments to its memorandum and articles.
The company's filings also describe its capital structure, including Class A ordinary shares, Class B ordinary shares with higher voting rights, warrants issued in public offerings, securities purchase agreements, placement agency arrangements and Form F-1 registration statement disclosures. These records connect financing activity and share-capital matters to BYAH's public-company governance and reporting obligations.
Park Ha Biological Technology Co., Ltd. has priced a registered direct offering of up to 1,133,332 Class A ordinary shares and pre-funded warrants to purchase up to 200,000 Class A shares at a combined price of $1.50 per security. The Company expects gross proceeds of approximately $2.0 million, with closing anticipated on or about June 15, 2026, subject to customary conditions. Net proceeds are intended for general corporate and working capital purposes.
The securities are being issued under an effective Form F-3 shelf registration statement that was declared effective on June 8, 2026, and a prospectus supplement and accompanying prospectus will be filed with the SEC. D. Boral Capital LLC is acting as the sole placement agent. Park Ha Biological operates the “Park Ha” skincare brand, with five directly operated stores and 22 franchisees in China as of October 31, 2025.
Park Ha Biological Technology Co., Ltd. entered a comprehensive strategic partnership with Star Plus Action (HK) Limited, a wholly owned unit of Hong Kong–listed Star Plus Legend Holdings Limited. The goal is to build an AI-powered skincare and health ecosystem in the beauty and wellness sector.
The partners have launched their first collaborative smart product, the pilot “AI Nutritionist,” and plan a full-chain intelligent service system featuring AI-powered store managers and AI-driven professional skincare specialists. These tools aim to digitalize store operations and provide personalized skincare and wellness recommendations for general wellness and cosmetic purposes only.
The company positions this collaboration as a key step in evolving from a pure skincare brand to a broader health and wellness ecosystem. As of April 30, 2025, Park Ha Biological operated three directly owned stores and 39 franchise locations in China under its “Park Ha” and “Geni” brands.
Park Ha Biological Technology Co., Ltd. has elected to use the Nasdaq home country practice exemption, allowing it to follow Cayman Islands corporate governance practices instead of certain Nasdaq Rule 5600 Series requirements. Cayman counsel Ogier issued a legal opinion stating these governance practices are not prohibited under Cayman law or the company’s memorandum and articles of association.
A copy of Ogier’s home country exemption letter is filed as an exhibit. Apart from the exempted areas, the company states its corporate governance practices do not differ significantly from those of U.S. domestic companies listed on Nasdaq.
Park Ha Biological Technology Co., Ltd. files Amendment No. 2 to its Form F-3 registration statement to furnish updated exhibits. The amendment states it updates Exhibits 4.1, 4.3 and 4.4 and that no other changes were made to the previously filed prospectus.
Park Ha Biological Technology Co., Ltd. registered a shelf of up to $300,000,000 of securities, including Class A ordinary shares, warrants, debt securities, rights, units and related instruments, to be offered from time to time.
The prospectus states the Company’s Class A Ordinary Shares trade on Nasdaq under BYAH and discloses a closing price of $1.14 per share and a public float of $5.14 million based on 4,510,446 shares as of April 15, 2026. The shelf will be used for one or more offerings with terms set in prospectus supplements; cash‑flow treatment and final offering mixes will be specified in those supplements.
Park Ha Biological Technology Co., Ltd. files Amendment No. 2 to its Form 20-F to address SEC comments by expanding disclosure on its variable interest entity (VIE) structure, PRC regulatory risks and financial review items.
The company explains that operations are conducted through PRC subsidiaries and VIEs, which it consolidates for accounting purposes but does not own directly. It highlights evolving PRC oversight of overseas listings, data security and CSRC filing requirements, and details potential impacts of the Holding Foreign Companies Accountable Act on its Nasdaq listing. As of October 31, 2025, there were 296,488 Class A ordinary shares and 381,000 Class B ordinary shares issued and outstanding, and in August 2025 the Cayman holding company contributed US$1.4 million to its WFOE subsidiary in China.
Park Ha Biological Technology Co., Ltd. filed Amendment No. 1 to its Form 20-F to expand risk, structural and financial disclosures in response to an SEC comment letter. The amendment enhances discussion of its Cayman holding company and PRC VIE structure, PRC regulatory, cybersecurity and HFCAA-related risks, and cash-transfer constraints within the group. It also revises MD&A to address fewer franchise contracts, share-based compensation and credit losses, and updates the audited financial statements and auditor’s report. As of October 31, 2025, the company had 296,488 Class A ordinary shares and 381,000 Class B ordinary shares issued and outstanding, and in August 2025 it transferred US$1.4 million from the Cayman parent to its WFOE subsidiary.
Park Ha Biological Technology Co., Ltd. filed a Form F-3 shelf registration to offer up to $300,000,000 of Class A ordinary shares and various securities, to be sold from time to time under prospectus supplements. The company warns of PRC regulatory, cybersecurity and HFCAA/PCAOB risks and discloses prior financings, corporate restructurings, and a January 28, 2026 follow-on unit offering.
Park Ha Biological Technology Co., Ltd. director Shan Yanan has filed an initial Form 3 insider ownership report. The available data shows no reported transactions or derivative positions, and no share holdings are detailed in this snapshot of the filing.